Neurodegenerative collaboration seeks novel drug candidates 

Neurimmune has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical, which is focused on creating antibody drugs against new therapeutic targets in the field of neurodegenerative diseases utilising Neurimmune’s proprietary Reverse Translational Medicine (RTM) technology platform, an antibody drug creation approach. 

Background 

In November 2017, Ono and Neurimmune signed a first drug discovery collaboration agreement to identify and develop human antibodies using the RTMTM technology platform. 

The new collaboration 

The companies aim to generate and validate human-derived monoclonal antibodies against Ono’s newly selected drug targets.  

Official comments  

“We are excited to expand our long-term trusted partnership with Ono, a global pioneer of innovative medicines,” said Jan Grimm, CSO of Neurimmune. “The joint goal of the collaboration is to discover novel drug candidates for the treatment of neurodegenerative diseases using RTM technology.” 

“We extremely appreciate Neurimmune’s RTMTM technology platform as an excellent antibody creation technology through our drug discovery projects.” said Toichi Takino, Senior Executive Officer / Executive Director, Discovery & Research of Ono Pharmaceutical. “Through this new collaboration, we will expand our central nervous system disease portfolio and work to deliver innovative medicines to patients with neurodegenerative diseases.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free